Search results
Results from the WOW.Com Content Network
The human protein is also frequently referred to as HER2 (human epidermal growth factor receptor 2) or CD340 (cluster of differentiation 340). [5] [6] [7]
She was part of the investigative team who discovered that the HER2/neu molecule is a tumor-specific marker, or antigen. [ 4 ] [ 5 ] She is the founding editor in chief of JAMA Oncology .
The following is a table of drugs organized by their year of discovery. Naturally occurring chemicals in plants, including alkaloids, have been used since pre-history.In the modern era, plant-based drugs have been isolated, purified and synthesised anew.
The ErbB family of proteins contains four receptor tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered member. In humans, the family includes Her1 (EGFR, ErbB1), Her2 , Her3 , and Her4 . The gene symbol, ErbB, is derived from the name of a viral oncogene to which these receptors are ...
In 1986 Axel Ullrich, a German scientist working at Genentech, first discovered the Her-2 protein and gave a conference about it in which Slamon was present.Afterwards Slamon proposed to work together, since he suspected that a mutation in Her-2 might cause cancer, eventually they found a kind of aggressive breast cancer with a mutation in the gene responsible for the Her-2 protein and started ...
This is an accepted version of this page This is the latest accepted revision, reviewed on 20 December 2024. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on the ...
1994: The first breast cancer gene is discovered. BRCA I was discovered by researchers at the King laboratory at UC Berkeley in 1990 but was first cloned in 1994. BRCA II, the second key gene in the manifestation of breast cancer was discovered later in 1994 by Professor Michael Stratton and Dr. Richard Wooster.
Alpelisib is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.